Where does your hair loss stage actually rank?

In the general Caucasian male population, Norwood II and III are the most commonly observed stages in younger adults. By the fifties and sixties, Norwood IV and V become the modal stages. The most common stage at any given time depends heavily on the age distribution of the group being considered.

Finasteride (an oral prescription medication, also marketed as Propecia) and minoxidil (a topical or oral treatment available over the counter in many countries) are the two treatments with the strongest clinical evidence for slowing or partially reversing AGA. Both work by different mechanisms: finasteride reduces DHT production; minoxidil extends the hair growth phase. Neither is a permanent cure and both require ongoing use to maintain results. Early treatment generally produces better outcomes. Low-level laser therapy (LLLT) and platelet-rich plasma (PRP) have emerging evidence but are less established.

Yes. Female pattern hair loss (FPHL) typically presents as diffuse crown thinning without significant frontal recession, which is why the Ludwig scale is used rather than Norwood. The hormonal drivers overlap with male AGA (androgens play a role) but oestrogen is also protective, which is why FPHL often accelerates at menopause. Minoxidil is approved for women and is the primary medical treatment. Finasteride is used off-label in post-menopausal women in some countries but is contraindicated in women who may become pregnant.

Androgenetic alopecia is driven by dihydrotestosterone (DHT), a potent androgen derived from testosterone by the enzyme 5-alpha reductase. DHT binds to androgen receptors in genetically susceptible hair follicles and progressively miniaturises them over successive growth cycles: each cycle produces a thinner, shorter hair until the follicle eventually stops producing visible hair altogether. The follicle is not destroyed but dormant; this is why finasteride (which inhibits 5-alpha reductase and reduces DHT levels by approximately 70%) can sometimes reverse miniaturisation in follicles that have not yet been dormant too long. Genetic susceptibility is polygenic and inherited from both parents, not solely the maternal side as the popular folk theory holds.

The pivotal clinical trials for finasteride 1mg (Propecia) published in the Journal of the American Academy of Dermatology found that 86% of men assigned to finasteride halted progression over a two-year period, compared to 42% on placebo. Approximately 65% of men on finasteride showed visible regrowth at two years. These figures come from male patients aged 18 to 41 with mild to moderate AGA; efficacy in older men and in those with advanced loss (Norwood V-VII) is lower. Finasteride works by reducing serum DHT levels by approximately 70%. It requires continuous use: discontinuation results in hair loss resuming within 12 months in most users, and within two years most regrowth from finasteride is typically lost.

Minoxidil's mechanism in hair loss is not fully understood, but it is believed to work primarily by prolonging the anagen (active growth) phase of the hair cycle and by widening blood vessels around the follicle to improve nutrient delivery. It was originally developed as an oral antihypertensive and was found to cause hypertrichosis (excess hair growth) as a side effect, which led to its reformulation as a topical treatment. Topical minoxidil 5% applied twice daily has been shown in randomised trials to halt progression in approximately 60% of users and produce visible regrowth in around 40% after 12 months. Oral minoxidil at low doses (0.625mg to 2.5mg daily) has shown comparable or superior results in observational data and is increasingly used off-label where topical tolerability is an issue.

Stress typically causes telogen effluvium, a diffuse shedding in which a large proportion of follicles simultaneously enter the resting (telogen) phase and shed 2 to 3 months after the triggering event. This is distinct from androgenetic alopecia and is generally reversible. Telogen effluvium related to acute stress, surgery, illness, or crash dieting typically resolves within 3 to 6 months once the trigger is removed, with regrowth completing over the following 6 to 12 months. However, chronic, sustained psychosocial stress may accelerate the timeline of genetically programmed AGA in susceptible individuals by increasing cortisol and affecting androgen metabolism, according to research from the University of California at Irvine published in 2021. The key distinction is that telogen effluvium from acute stress does not cause permanent loss; chronic stress may modestly accelerate permanent loss in those already predisposed.

Follicular Unit Transplantation (FUT) involves removing a strip of scalp from the donor area (usually the back and sides) and dissecting individual follicular units from it under a microscope before implanting them in the recipient area. FUT can yield a larger number of grafts per session (often 3,000 to 4,000) and has the advantage that follicles are handled less individually during extraction, potentially improving survival rates. It leaves a linear scar at the donor site. Follicular Unit Extraction (FUE) removes individual follicular units directly from the scalp using a small punch tool (0.8 to 1.0mm diameter), leaving small circular scars rather than a linear one. FUE is preferred when patients want to wear their hair very short. Graft survival rates for experienced surgeons are broadly similar between methods. The International Society of Hair Restoration Surgery estimates approximately 700,000 hair transplant procedures are performed annually worldwide, with FUE now accounting for over 60% of procedures.

A systematic review published in the British Journal of Dermatology (2012) analysing 23 studies found that hair loss was associated with significant psychological distress in both men and women, including reduced self-esteem, increased anxiety about appearance, and lower self-confidence in social and professional settings. The impact was generally larger in women than in men, partly because hair loss deviates more strongly from social norms for women. For men, studies from the University of Pennsylvania found that early-onset hair loss (beginning in the twenties) was associated with greater psychological distress than later onset, likely because it is less normatively expected. Importantly, the psychological burden did not correlate reliably with the severity of hair loss, suggesting that individual expectations and social context matter as much as the biological degree of loss.

Platelet-rich plasma therapy involves drawing a small amount of the patient's blood, centrifuging it to concentrate the platelet-containing plasma, and injecting it into the scalp to stimulate follicle activity. The theoretical mechanism is that growth factors in the concentrated plasma promote follicle health and extend the anagen phase. A 2019 meta-analysis in Dermatologic Surgery pooling data from 19 randomised controlled trials found that PRP produced statistically significant increases in hair count and thickness compared with control groups, with a mean increase of approximately 45 additional hairs per square centimetre. However, study quality was generally low, follow-up periods were short (mostly under 6 months), and there is no standardised protocol for PRP preparation or injection frequency. The American Academy of Dermatology considers PRP a promising but insufficiently studied adjunct to established treatments rather than a standalone first-line option.

Male pattern baldness can technically begin as early as the mid-to-late teens in highly susceptible individuals, though noticeable recession more commonly emerges in the early to mid twenties. The frequently cited rule of thumb is that prevalence tracks roughly with decade of life for Caucasian men: approximately 20% show noticeable AGA in their twenties, 30% in their thirties (the so-called 20/30/40 rule, though the actual figures are somewhat higher than this). A 2011 study in the Journal of Investigative Dermatology following a large Korean cohort found that men who showed any AGA by age 20 had significantly higher rates of advanced loss by age 40 compared with those whose loss began after 30, confirming that onset age is a predictor of eventual severity. Ethnicity modifies these patterns substantially, with Asian men typically showing onset about one decade later than age-matched Caucasian men.